These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36222298)

  • 21. LINC02389/miR-7-5p Regulated Cisplatin Resistance of Non-Small-Cell Lung Cancer via Promoting Oxidative Stress.
    Ma P; Han W; Meng C; Tan X; Liu P; Dong L
    Anal Cell Pathol (Amst); 2022; 2022():6100176. PubMed ID: 36311891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LINC01140 inhibits nonsmall cell lung cancer progression and cisplatin resistance through the miR-4742-5p/TACC1 axis.
    Wang Y; Li M; Zhang L; Chen Y; Ha M
    J Biochem Mol Toxicol; 2022 Jul; 36(7):e23048. PubMed ID: 35307914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
    Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
    Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
    Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
    Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
    EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of lncRNA EGFR‑AS1 is associated with a poor prognosis and promotes chemotherapy resistance in non‑small cell lung cancer.
    Xu YH; Tu JR; Zhao TT; Xie SG; Tang SB
    Int J Oncol; 2019 Jan; 54(1):295-305. PubMed ID: 30431074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
    Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
    Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circ_0011292 knockdown mitigates progression and drug resistance in PTX-resistant non-small-cell lung cancer cells by regulating miR-433-3p/CHEK1 axis.
    Jin M; Zhang F; Li Q; Xu R; Liu Y; Zhang Y
    Thorac Cancer; 2022 May; 13(9):1276-1288. PubMed ID: 35348291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
    Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
    EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDKN1A upregulation and cisplatin‑pemetrexed resistance in non‑small cell lung cancer cells.
    Zamagni A; Pasini A; Pirini F; Ravaioli S; Giordano E; Tesei A; Calistri D; Ulivi P; Fabbri F; Foca F; Delmonte A; Molinari C
    Int J Oncol; 2020 Jun; 56(6):1574-1584. PubMed ID: 32236605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
    Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
    Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Knockdown of lncRNA ANRIL inhibits the development of cisplatin resistance by upregulating miR‑98 in lung cancer cells.
    Wang X; Zhang G; Cheng Z; Dai L; Jia L; Jing X; Wang H; Zhang R; Liu M; Jiang T; Yang Y; Yang M
    Oncol Rep; 2020 Sep; 44(3):1025-1036. PubMed ID: 32705261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel cancer-germline gene DAZL promotes progression and cisplatin resistance of non-small cell lung cancer by upregulating JAK2 and MCM8.
    Zhou L; Le MNU; Du Y; Chen X; Jin M; Xiang H; Xia LE; Zhou J; He J; Ning Y
    Gene; 2024 Jul; 916():148449. PubMed ID: 38588931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circ_0072088 knockdown contributes to cisplatin sensitivity and inhibits tumor progression by miR-944/LASP1 axis in non-small cell lung cancer.
    Zhang L; Wu Y; Hou C; Li F
    J Gene Med; 2022 May; 24(5):e3414. PubMed ID: 35106879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circ_0000079 Decoys the RNA-Binding Protein FXR1 to Interrupt Formation of the FXR1/PRCKI Complex and Decline Their Mediated Cell Invasion and Drug Resistance in NSCLC.
    Chen C; Zhang M; Zhang Y
    Cell Transplant; 2020; 29():963689720961070. PubMed ID: 32951448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PLAU promotes growth and attenuates cisplatin chemosensitivity in ARID1A-depleted non-small cell lung cancer through interaction with TM4SF1.
    Zheng Y; Zhang L; Zhang K; Wu S; Wang C; Huang R; Liao H
    Biol Direct; 2024 Jan; 19(1):7. PubMed ID: 38229120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-25-3p promotes cisplatin resistance in Non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route.
    Sun B; Hu N; Cong D; Chen K; Li J
    Bioengineered; 2021 Dec; 12(1):3219-3228. PubMed ID: 34266345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.